...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Biomolecules & therapeutics >A Novel In Situ Gel Formulation of Ranitidine for Oral Sustained Delivery
【24h】

A Novel In Situ Gel Formulation of Ranitidine for Oral Sustained Delivery

机译：雷尼替丁口服持续递送的新型原位凝胶制剂

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The main purpose of this study was to develop a novel, in situ gel system for sustained delivery of ranitidine hydrochloride. Ranitidine in situ gels at 0.2%, 0.5%, and 1.0% gellan gum concentration (w/v) were prepared, respectively, and characterized in terms of preparation, viscosity and in vitro release. The viscosity of the gellan gum formulations in solution increased with increasing concentrations of gellan gum. In vitro study showed that the release of ranitidine from these gels was characterized by an initial phase of high release (burst effect) and translated to the second phase of moderate release. Single photon emission computing tomography technique was used to evaluate the stomach residence time of gel containing Tc-99m tracer. The animal experiment suggested in situ gel had feasibility of forming gels in stomach and sustained the ranitidine release from the gels over the period of at least 8 h. In conclusion, the in situ gel system is a promising approach for the oral delivery of ranitidine for the therapeutic effects improvement.
机译：这项研究的主要目的是开发一种新型的原位凝胶系统，用于持续递送盐酸雷尼替丁。分别制备浓度为0.2％，0.5％和1.0％吉兰糖胶（w / v）的雷尼替丁原位凝胶，并根据制备，粘度和体外释放进行表征。结冷胶制剂在溶液中的粘度随着结冷胶浓度的增加而增加。体外研究表明，雷尼替丁从这些凝胶中的释放以高释放的初始阶段（爆发效应）为特征，并转化为中度释放的第二阶段。使用单光子发射计算机断层扫描技术评估含Tc-99m示踪剂的凝胶在胃中的停留时间。动物实验表明，原位凝胶可在胃中形成凝胶，并在至少8小时内维持雷尼替丁从凝胶中的释放。总之，原位凝胶系统是雷尼替丁口服给药以改善治疗效果的一种有前途的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号